Preparation and biodistribution of [18F]FP2OP as myocardial perfusion imaging agent for positron emission tomography

被引:26
|
作者
Mou, Tiantian [1 ]
Jing, Huihui [1 ]
Yang, Wenjiang [1 ]
Fang, Wei [2 ,3 ]
Peng, Cheng [4 ]
Guo, Feng [2 ,3 ]
Zhang, Xianzhong [1 ]
Pang, Yan [1 ]
Ma, Yunchuan [4 ]
机构
[1] Beijing Normal Univ, Coll Chem, Minist Educ, Key Lab Radiopharmaceut, Beijing 100875, Peoples R China
[2] Chinese Acad Med Sci, Cardiovasc Inst, Dept Nucl Med, Beijing 100037, Peoples R China
[3] Chinese Acad Med Sci, Fu Wai Hosp, Beijing 100037, Peoples R China
[4] Capital Med Univ, Xuan Wu Hosp, PET Ctr, Beijing 100053, Peoples R China
基金
中国国家自然科学基金; 北京市自然科学基金;
关键词
Positron emission tomography; Myocardial perfusion imaging; F-18]FP2OP; Mitochondria complex I; FLOW TRACER; KINETIC-ANALYSIS; PET; COMPLEX; EXPRESSION;
D O I
10.1016/j.bmc.2009.12.022
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Myocardial extractions of pyridaben, a mitochondrial complex I (MC-I) inhibitor, is well correlated with blood flow. Based on the synthesis and characterization of pyridaben analogue 2-tert-butyl-5-[2-(2-[F-18]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([F-18]FP2OP), this study assessed its potential to be developed as myocardial perfusion imaging (MPI) agent. Methods: The tosylate labeling precursor 2-(2-(4-(tert-butyl-5-chloro-6-oxo-1,6-dihydro-pyridazin-4-yloxymethyl)benzyloxy)ethoxy) ethyl ester (OTs-P2OP) and the nonradioactive 2-tert-butyl-5-[2-(2-[F-19]fluroethoxy)ethoxy]benzyloxy]-4-chloro-2H-pyridazin-3-one ([F-19]FP2OP) were synthesized and characterized by IR, H-1 NMR, C-13 NMR and MS analysis. By substituting tosyl of precursor OTs-P2OP with F-18, the radiolabeled complex [F-18]FP2OP was prepared and further evaluated for its in vitro physicochemical properties, in vivo biodistribution, the metabolic stability in mice, ex vivo autoradiography and cardiac PET/CT imaging. Results: Starting with [F-18]F Kryptofix 2.2.2./K2CO3 solution, the total reaction time for [F-18]FP2OP was about 100 min, with final high-performance liquid chromatography purification included. Typical decay-corrected radiochemical yield stayed at 41 +/- 5.3%, the radiochemical purity, 98% or more. Biodistribution in mice showed that the heart uptake of [F-18]FP2OP was 41.90 +/- 4.52% ID/g at 2 min post-injection time, when the ratio of heart/liver, heart/lung and heart/blood reached 6.83, 9.49 and 35.74, respectively. Lipophilic molecule was further produced by metabolized [F-18]FP2OP in blood and urine at 30 min. Ex vivo autoradiography demonstrates that [F-18]FP2OP may have high affinity with MC-I and that can be blocked by [F-19] FP2OP or rotenone (a known MC-I inhibitor). Cardiac PET images were obtained in a Chinese mini-swine at 5, 15, 30 and 60 min post-injection time with high quality. Conclusion: [F-18]FP2OP was synthesized with high radiochemical yield. The promising biological properties of [F-18]FP2OP suggest high potential as MPI agent for positron emission tomography in the future. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1312 / 1320
页数:9
相关论文
共 50 条
  • [41] Novel methodology for labelling mesoporous silica nanoparticles using the 18F isotope and their in vivo biodistribution by positron emission tomography
    Santiago Rojas
    Juan Domingo Gispert
    Cristina Menchón
    Herme G. Baldoví
    Mireia Buaki-Sogo
    Milagros Rocha
    Sergio Abad
    Victor Manuel Victor
    Hermenegildo García
    José Raúl Herance
    Journal of Nanoparticle Research, 2015, 17
  • [42] Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography
    Hae-Won Shin
    Jae Seung Kim
    Minyoung Oh
    Sooyeoun You
    Young Jin Kim
    Juyeon Kim
    Mi-Jung Kim
    Sun Ju Chung
    Neurological Sciences, 2015, 36 : 269 - 274
  • [43] Clinical features of drug-induced parkinsonism based on [18F] FP-CIT positron emission tomography
    Shin, Hae-Won
    Kim, Jae Seung
    Oh, Minyoung
    You, Sooyeoun
    Kim, Young Jin
    Kim, Juyeon
    Kim, Mi-Jung
    Chung, Sun Ju
    NEUROLOGICAL SCIENCES, 2015, 36 (02) : 269 - 274
  • [44] Imaging of Myocardial Ischemia-Reperfusion Injury Using Sodium [18F]Fluoride Positron Emission Tomography/Computed Tomography in Rats and Humans
    Choi, Hongyoon
    Han, Jeong Hee
    Lim, Sue Yeon
    Lee, Inki
    Cho, Young-Seok
    Chun, Eun Ju
    Lee, Won Woo
    MOLECULAR IMAGING, 2017, 16
  • [45] Machine learning models for positron emission tomography myocardial perfusion imaging
    Williams, Michelle C.
    JOURNAL OF NUCLEAR CARDIOLOGY, 2024, 32
  • [46] The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression
    Michael J. Fisher
    Sandip Basu
    Eva Dombi
    Jian Q. Yu
    Brigitte C. Widemann
    Avrum N. Pollock
    Avital Cnaan
    Hongming Zhuang
    Peter C. Phillips
    Abass Alavi
    Journal of Neuro-Oncology, 2008, 87 : 165 - 171
  • [47] The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression
    Fisher, Michael J.
    Basu, Sandip
    Dombi, Eva
    Yu, Jian Q.
    Widemann, Brigitte C.
    Pollock, Avrum N.
    Cnaan, Avital
    Zhuang, Hongming
    Phillips, Peter C.
    Alavi, Abass
    JOURNAL OF NEURO-ONCOLOGY, 2008, 87 (02) : 165 - 171
  • [48] [18F]Trifluoroiodomethane - Enabling Photoredox-mediated Radical [18F]Trifluoromethylation for Positron Emission Tomography
    Veth, Lukas
    Windhorst, Albert D.
    Vugts, Danielle J.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2025, 64 (08)
  • [49] Measurement of changes in endogenous serotonin level by positron emission tomography with [18F]altanserin
    Ikoma, Yoko
    Takuwa, Hiroyuki
    Nishino, Asuka
    Maeda, Jun
    Kawamura, Kazunori
    Obata, Takayuki
    Zhang, Ming-Rong
    Higuchi, Makoto
    Suhara, Tetsuya
    ANNALS OF NUCLEAR MEDICINE, 2021, 35 (08) : 955 - 965
  • [50] Preparation of [18F]β-CFT-FP and [11C]β-CFT-FP, selective radioligands for visualisation of the dopamine transporter using positron emission tomography (PET)
    Kämäräinen, EL
    Kyllönen, T
    Airaksinen, A
    Lundkvist, C
    Yu, MX
    Någren, K
    Sandell, J
    Langer, O
    Vepsäläinen, J
    Hiltunen, J
    Bergström, K
    Lötjönen, S
    Jaakkola, T
    Halldin, C
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2000, 43 (12) : 1235 - 1244